<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129619</url>
  </required_header>
  <id_info>
    <org_study_id>OM-201</org_study_id>
    <nct_id>NCT04129619</nct_id>
  </id_info>
  <brief_title>A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Phase 2, Responsive Adaptive Randomization Study of ORP-101 in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrphoMed, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OrphoMed, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of ORP-101 versus placebo on stool consistency and&#xD;
      abdominal pain in patients with Irritable Bowel Syndrome with Diarrhea (IBS-D). It will also&#xD;
      assess the safety and tolerability of ORP-101 in patients with IBS-D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to evaluate the efficacy, safety and tolerability of ORP-101&#xD;
      in patients with IBS-D. This is a randomized, double-blind, placebo-controlled, 3-arm,&#xD;
      12-week, parallel proof-of-concept study with 2 active arms (50 mg and 100 mg ORP-101, QD)&#xD;
      and 1 matching placebo arm, using a responsive adaptive randomization approach. After&#xD;
      screening, patients who qualify will enter the baseline symptom assessment period, during&#xD;
      which they will be instructed on completion of an electronic diary for daily collection of&#xD;
      data related to their IBS symptoms, bowel function and loperamide rescue usage (not allowed&#xD;
      during baseline).&#xD;
&#xD;
      Patients who meet all entry criteria will be randomized to receive one of two different doses&#xD;
      of ORP-101 tablets or placebo for 12 weeks. The study drug will be taken once daily,&#xD;
      approximately 30 minutes prior to breakfast. Patients will return to the clinic on Days 14,&#xD;
      28, 56, 84 (12 weeks) and 2 weeks after dosing has completed (Day 98) for a follow-up visit.&#xD;
&#xD;
      Study subjects will include both male and female adults. Approximately 320 patients with&#xD;
      IBS-D will be randomized to receive study drug or placebo. Randomization will be stratified&#xD;
      by history of cholecystectomy/gallbladder agenesis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 22, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>Composite responders are defined as participants who met the daily response criteria for at least 50% of the days with diary entries over the 12-week interval. A participant must meet both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Average of daily stool consistency response for all reported bowel movements on the specific day: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Responders in Daily Worst Abdominal Pain Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>Pain responders over the interval from Weeks 1-12 are defined as those patients who meet the daily pain response criteria for at least 50% of days with diary entry during the interval. To be eligible to be a responder, a patient must have a minimum of 60 days of diary entries over the 12-week interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Responders in Daily Stool Consistency Scores</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Stool consistency responders over the interval from Weeks 1-12 are defined as those patients who meet the daily stool consistency response criteria for at least 50% of days with diary entry during the interval. To be eligible to be a responder, a patient must have a minimum of 60 days of diary entries over the 12-week interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who are Responders in IBS Global Symptom Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>IBS Global Symptom Score: Change from baseline for interval from Weeks 1-12: A responder is defined as a patient who has an IBS global symptom score of 0 (none) or 1 (mild) or daily IBS symptom score improved by ≥ 2.0 compared to the average in the week prior to randomization. A minimum of 60 days of diary entries over the 12-week interval is required for responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who are Responders in IBS Adequate Relief Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>IBS Adequate Relief: Percent of responders over the interval from Weeks 1-12. Responders are defined as those patients with a weekly response of &quot;Yes&quot; to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Modified Composite Responders Based on Responder Endpoints</measure>
    <time_frame>Week 12</time_frame>
    <description>A modified composite responder endpoint in which a daily responder will be defined as having both: 1) Pain response: worst abdominal pain score in the past 24 hours improved ≥ 30% compared to the average in the week prior to randomization. 2) Stool consistency response: all bowel movements on the specific day must have BSFS score &lt; 5 or the absence of a bowel movement if accompanied by ≥ 30% improvement in worst abdominal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Daily Abdominal Discomfort Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>Discomfort: Change from baseline in daily abdominal discomfort scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Daily Abdominal Bloating Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>Bloating: Change from baseline in daily abdominal bloating scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Movements Per Day</measure>
    <time_frame>Week 12</time_frame>
    <description>Frequency: Change from baseline in mean number of bowel movements per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Incontinence Free Days</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from baseline in mean number of bowel incontinence episodes per day as well as the number of incontinence-free days</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">321</enrollment>
  <condition>Irritable Bowel Syndrome With Diarrhea</condition>
  <arm_group>
    <arm_group_label>ORP-101 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORP-101 (50 mg) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORP-101 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORP-101 (100 mg), once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORP-101</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>ORP-101 100 mg</arm_group_label>
    <arm_group_label>ORP-101 50 mg</arm_group_label>
    <other_name>dibuprenorphine-ethyl-ether</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to comply with protocol, including completion of electronic daily&#xD;
             diary as required.&#xD;
&#xD;
          -  Has a diagnosis of IBS-D (Irritable Bowel Syndrome with Diarrhea) and meets the Rome&#xD;
             IV Criteria, by history, for both IBS and IBS-D.&#xD;
&#xD;
          -  Has abdominal pain intensity score, and stool consistency as determined by protocol&#xD;
             and assessed by Investigator for the week prior to randomization.&#xD;
&#xD;
          -  Has not used loperamide within the 14 days prior to randomization.&#xD;
&#xD;
          -  Is on a stable diet for the past 12 weeks and is not planning to change lifestyle&#xD;
             and/or diet during study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically relevant pancreatic conditions including pancreatitis, pancreas&#xD;
             divisum, or Sphincter of Oddi (SO) dysfunction with pancreatic manifestations.&#xD;
&#xD;
          -  History of biliary pathology including acute cholecystitis within 6 months or biliary&#xD;
             pain including post-cholecystectomy pain.&#xD;
&#xD;
          -  Patients who have had biliary sphincterotomy with post-procedure persistent abnormal&#xD;
             liver function transaminases (LFTs).&#xD;
&#xD;
          -  Planned elective surgery within the next 4 months.&#xD;
&#xD;
          -  Significant and/or severe medical illnesses such as cardiovascular, neurological,&#xD;
             infectious, renal, hepatic or respiratory disorders that would interfere with the&#xD;
             patient's medical care, participation in, or conduct of the study.&#xD;
&#xD;
          -  History of intestinal obstruction, stricture, toxic megacolon, GI (gastro-intestinal)&#xD;
             perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic&#xD;
             colitis, or impaired intestinal circulation (e.g. aorto-iliac disease).&#xD;
&#xD;
          -  History of lactose intolerance uncontrolled on a lactose-free diet, or other&#xD;
             malabsorption syndromes (e.g. fructose malabsorption).&#xD;
&#xD;
          -  Dysphagia or difficulty swallowing pills.&#xD;
&#xD;
          -  History of inflammatory bowel disease, celiac disease, Clostridium difficile colitis&#xD;
             or have had recent unexplained GI bleeding within 3 months prior to screening.&#xD;
&#xD;
          -  History of major gastric, hepatic, pancreatic or intestinal surgery (appendectomy,&#xD;
             hemorrhoidectomy, or polypectomy allowed as long as occurred &gt; 3 months prior to trial&#xD;
             screening; uncomplicated laparoscopic or open cholecystectomy is allowed if no history&#xD;
             of post-operative biliary tract pain and surgery occurred &gt; 3 months prior to&#xD;
             screening).&#xD;
&#xD;
          -  Patients &gt;40 years of age at high risk for colon cancer must have had a screening&#xD;
             colonoscopy within the past 3 years prior to trial screening visit or &gt; 50 years of&#xD;
             age, must have had a normal screening colonoscopy within the past 10 years prior to&#xD;
             trial screening visit. Patients with Lynch Syndrome or Familial Polyposis are excluded&#xD;
             from the study.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Achieve Clinical Research (Site 155)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Phoenix Southeast (Site 123)</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies - Phoenix (Site 116)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management - BTC (Site 165)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Orange Grove Family Practice (Site 118)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management - BTC (Site 130)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners - ClinEdge (Site 103)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Research Center (Site 158)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Foundation (Site 136)</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imagine Research of Palm Beach County (Site 187)</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Lakeland (Site 167)</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research LLC (Site 139)</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research, Maitland - Inpatient (Site 141)</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oviedo Medical Research (Site 140)</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida (Site 186)</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - St. Petersburg (Site 132)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agile Clinical Research Trials, LLC (Site 163)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Diseases, Inc. Research (Site 137)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Site 169)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>In Quest Medical Research, LLC (Site 131)</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GNP Research (Site 145)</name>
      <address>
        <city>Valdosta</city>
        <state>Georgia</state>
        <zip>31605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials - ClinEdge (Site 133)</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Chicago (Site 120)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigators Research Group, LLC (Site 188)</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Allaw (Site 102)</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC (Site 159)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (Site 115)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AES-DRS-Synexus Clinical Research US, Inc.-Minneapolis (site 114)</name>
      <address>
        <city>Richfield</city>
        <state>Minnesota</state>
        <zip>55423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research (Site 175)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Omaha (Site 113)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - McGill Family Practice, P.C. (Site 126)</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jubilee Clinical Research - BTC (Site 162)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Clinical Research (Site 179)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources Inc. (Site 176)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Scientific (Site 153)</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Gastrointestinal Research Group LLP (Site 107)</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Queens (Site 119)</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research PLLC (Site 174)</name>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates LLC - ClinEdge (Site 164)</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC - ClinEdge (Site 147)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC - ClinEdge (Site 146)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research, LLC - ClinEdge (SIte 111)</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury LLC (Site 110)</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington (Site 185)</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem (Site 124)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Akron (Site 122)</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research (Site 150)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Cincinnati (Site 127)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Columbus (Site 108)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research (Site 149)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington Davis Inc (Site 144)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PriMed Clinical Research - ClinEdge (Site 121)</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research (Site 151)</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research international (Site 180)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tristar Clinical Investigations, P.C. (Site 168)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC (Site 171)</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Research Partners LLC - BTC (Site 157)</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus clinical Research US, Inc. - Greer (Site 105)</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch, LLC (Site 129)</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jackson Clinic PA - ClinEdge (Site 135)</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development (Site 181)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - Austin (Site 178)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Trials (SIte 142)</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions (Site 125)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Group US, LLC - Missouri City - Hunt (Site 156)</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research - LinQ Research - ERN (Site 109)</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - San Antonio (Site 112)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>48229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas Incorporated - ClinEdge (Site 134)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Salt Lake City (Site 101)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute (Site 117)</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads Inc. (Site 173)</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center of Gastrointestinal Health (Site 152)</name>
      <address>
        <city>Petersburg</city>
        <state>Virginia</state>
        <zip>23805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center - ClinEdge (Site 148)</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Exemplar Research, Inc. - Morgantown (Site 172)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://prevailibsdstudy.com</url>
    <description>For potential patients/subjects, if interested in the study, please visit this website and complete the survey</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>IBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ether</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

